AstraZeneca Pharma India Limited has detailed the tax deduction at source (TDS) rates applicable to the final dividend of ₹36 per share for the financial year 2025-26. The company has fixed July 31, 2026, as the record date to determine shareholder eligibility, with the dividend payout subject to approval at the 47th Annual General Meeting scheduled for August 10, 2026. Shareholders must submit necessary documentation by July 31, 2026, 17:00 hrs IST, to ensure the correct tax rate is applied; failure to do so will result in tax deduction at the maximum applicable rate.

For resident shareholders, tax will not be deducted if the total dividend amount for FY27 does not exceed ₹10,000. Where applicable, the TDS rate is 10% for shareholders with a valid PAN, while those without or with an invalid PAN will face a 20% deduction. Shareholders may submit Form 121 (erstwhile forms 15G and 15H) or a lower withholding certificate to claim a nil rate, provided specific conditions are met.

Non-resident shareholders are subject to a 20% tax rate plus surcharge and cess, unless they opt for the more beneficial Double Tax Avoidance Treaty (DTAA) rates. To avail treaty benefits, non-residents, including Foreign Institutional Investors (FIIs) and Foreign Portfolio Investors (FPIs), must furnish documents such as a Tax Residency Certificate (TRC) valid in August 2026, a self-declaration in online Form 41, and proof of no Permanent Establishment in India.

TDS Rates for Resident Shareholders

TDS Rates for Non-Resident Shareholders

The company emphasized that residential status will be determined based on records with the Depository Participants or the company as of the record date. Shareholders with multiple accounts under different statuses but a single PAN should note that the highest applicable tax rate will be levied on their entire holding. Forms and declarations must be uploaded via the Registrar and Transfer Agent’s weblink by the specified deadline.

AstraZeneca Pharma India Limited has accepted the resignation of Ms. Bhavana Agrawal from the position of Chief Financial Officer (CFO) and Key Managerial Personnel, effective from the close of business hours on August 31, 2026. The resignation follows her appointment to a regional role within the AstraZeneca Group. The company disclosed this development in a filing submitted to the stock exchanges on July 21, 2026.

Regulatory Disclosures

The announcement was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company provided the necessary details as required under the SEBI Master Circular SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. Tanya Sanish, Company Secretary & Compliance Officer, signed the disclosure on behalf of the company.

Resignation Details

Ms. Bhavana Agrawal communicated her resignation to the Board of Directors on July 20, 2026. In her resignation letter, she expressed gratitude to the Board, senior management, and colleagues for their support during her tenure. The specific details regarding the new regional role or the appointment of a successor were not disclosed in the regulatory filing.